Expertise in
6
conditions

Olga Salamero

Barcelona, CT, ES 
Expertise in
6
conditions
Barcelona, CT, ES 

Overview

Olga Salamero practices practicing medicine in Barcelona, Spain.

Ms. Salamero is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Acute Promyelocytic Leukemia, Gaucher Disease Type 1, and Bone Marrow Transplant.

She is actively involved in clinical research, co-authoring 66 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Barcelona, CT, Spain
Other Locations
Bellaterra, CT, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML
Enrollment Status: Terminated
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drugs: CPI-613, Cytarabine, Mitoxantrone, Etoposide, Fludarabine, Filgrastim
Study Phase: Phase 3
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

66 Total Publications

Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies.
Journal: Leukemia & lymphoma
Published: July 26, 2026

Frequently Asked Questions about Olga Salamero

Is Olga Salamero a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Olga Salamero is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Olga Salamero participate in research or clinical trials?

Yes. Olga Salamero has published 66 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Olga Salamero's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Salamero's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile